This report introduces a framework to define and measure access to “essential innovative medicines” across Europe. It proposes criteria that combine clinical benefit, unmet need, and therapeutic advancement to identify medicines that deliver meaningful patient value. Using IQVIA data, the report analyzes uptake and availability across European countries, revealing wide variation in access and use despite centralized regulatory approval. Barriers include pricing negotiations, HTA outcomes, reimbursement delays, and health system capacity. The analysis highlights gaps between innovation approval and real-world patient benefit, and calls for more aligned policy approaches, improved measurement, and greater transparency to ensure timely and equitable access to high-value innovative medicines a

Join for free to read